drugset / Trial / NCT06854276

Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

NCT06854276

Phase 2 Not yet recruiting 80 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study employs a multicenter, randomized, open-label, positive drug-controlled, multiple ascending dose clinical trial design to comprehensively evaluate the safety, tolerability, immunogenicity, and pharmacokinetic characteristics of SSS06 injection in patients with chemotherapy-induced anemia from non-myeloid malignancies, while also exploring its potential efficacy.

Timeline

Start
2025-03-01
Primary completion
2027-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SSS06 Protein / enzyme biologic 200 ug
Subject SSS06 Protein / enzyme biologic 500 ug
Subject SSS06 Protein / enzyme biologic 800 ug
Comparator rhEPO Protein / enzyme biologic 36000 iu

Indications